Abstract

Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past 30 years due to the lack of early theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for bladder cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the wide use of the targeting peptides for intravesical theranostic techniques in bladder cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical application.

Details

Title
Advances in Research on Bladder Cancer Targeting Peptides: a Review
Author
Zheng, Bin 1   VIAFID ORCID Logo  ; Zhang, Pu 2   VIAFID ORCID Logo  ; Wang, Heng 2 ; Wang Jinxue 3 ; Liu, Zheng Hong 4 ; Zhang, DaHong 4   VIAFID ORCID Logo 

 Zhejiang Chinese Medical University, HangZhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924); Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou, China (GRID:grid.506977.a) (ISNI:0000 0004 1757 7957) 
 Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou, China (GRID:grid.506977.a) (ISNI:0000 0004 1757 7957) 
 Handan Central hospital, Handan, China (GRID:grid.506977.a) 
 Zhejiang Chinese Medical University, HangZhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924) 
Pages
711-718
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
ISSN
10859195
e-ISSN
15590283
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2589629450
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.